ライフサイエンスコーパス: ALP

1 ALP activity and calcium content analysis of MSCs-laden

2 ALP activity in osteoblasts and TRAP activity in RAW264.

3 ALP analysis, on the contrary, detected similar amounts

4 ALP and GGT were unrelated to adiposity.

5 ALP deserves routine monitoring, and the cause for an el

6 ALP is not a good proxy to assess Vtg levels in marine m

7 ALP levels significantly increased from day 3 to day 30

8 ALP response was defined as a >40% decrease from baselin

9 ALP was chosen as the biomarker due to its age-dependent

10 ALP was inversely associated with BMI (-0.018 kg/m(2) pe

11 ALP-catalyzed hydrolysis of p-nitrophenyl phosphate (pNP

12 ALP/OXP-specific T cells reacted immediately to the addi

13 ts prehospitalization (AST 25.9%, ALT 38.0%, ALP 56.8%, and TBIL 44.4%).

14 th CAD/MI (ALT OR 0.74, 95% CI 0.54 to 1.01, ALP OR 0.86, 95% CI 0.64 to 1.16 and GGT OR 1.08, 95% CI

15 omains in an ATN-1(alpha-actinin)- and ALP-1(ALP/Enigma)-dependent manner, where it contributes to th

16 limit of normal (ULN; AST 63.7%, ALT 63.5%, ALP 80.0%, and TBIL 75.7%).

17 19, both at admission (AST 66.9%, ALT 41.6%, ALP 13.5%, and TBIL 4.3%) and peak hospitalization (AST

18 peak hospitalization (AST 83.4%, ALT 61.6%, ALP 22.7%, and TBIL 16.1%).

19 ormal serum alkaline phosphatases (ALP) 74%; ALP above 1.5 times the upper limit of normal 13%; and c

20 of patients demonstrated a decline in aBSI, ALP, and PSA, respectively.

21 were reached by week 12, no patient achieved ALP response or remission.

22 ease of both the substrate and/or the active ALP, in a biodegradable and low-cost material such as ze

23 rbon electrode (SPCE) and antibodies against ALP (anti-ALP) were immobilized using carbodiimide bioco

24 Allopurinol (ALP) hypersensitivity is a major cause of severe cutaneo

25 Treatment with alsterpaullone (ALP) results in acquiring characteristics of the head or

26 Using MR, genetic predictors of ALT, ALP and gamma glutamyltransferase (GGT), were applied to

27 ce displayed increased plasma levels of ALT, ALP, and bilirubin as well as a significantly higher col

28 Genetically predicted ALT, ALP and GGT were not clearly associated with CAD/MI (ALT

29 AlfA, an ALP that pushes plasmids apart in Bacillus, relies on a

30 scein diphosphate as a signal reporter in an ALP-linked immunosorbent assay, the proposed system prov

31 s in groups 1 and 2, respectively, showed an ALP decline of more than 30% (P = 0.04).

32 s in groups 1 and 2, respectively, showed an ALP decline.

33 osorbent assays, the probe was coupled to an ALP-linked immunosorbent assay for the sensitive and sel

34 In this 3-year interim analysis, ALP concentrations were significantly reduced compared w

35 gnificantly and positively related with ANC, ALP, and ferritin, suggesting phthalates may be associat

36 ong baseline covariates, aBSI (P = 0.01) and ALP (P = 0.001) were significantly associated with OS, w

37 Median OS in patients with both aBSI and ALP decline (median, 134 wk) was significantly longer th

38 SH3 domains in an ATN-1(alpha-actinin)- and ALP-1(ALP/Enigma)-dependent manner, where it contributes

39 The mean levels of plasma Hcy, ALT and ALP were significantly reduced in responders within 10 w

40 drolysis adenosine-5'-triphosphate (ATP) and ALP can hydrolysis pyrophosphate, both reactions produce

41 defined as a >40% decrease from baseline and ALP remission as ALP normalization (if baseline ALP 1.67

42 of liver injury, particularly bilirubin and ALP, are used to stratify risk and assess treatment resp

43 genic markers), CD63, AnX2 (sEV markers) and ALP expression (mineralization marker) in the arterial m

44 differentiation via reduction of Osterix and ALP expression.

45 NX2, type X collagen (CoL10A1), Osterix, and ALP were not expressed.

46 One common feature of the PKA and ALP catalyzing process is that PKA can hydrolysis adenos

47 s tool has the potential to simplify PKA and ALP clinical measurement, thereby improving diagnostics

48 The detection limit for PKA and ALP were much lower than existing assays.

49 le of detecting the activity of both PKA and ALP.

50 the activity and inhibition of both PKA and ALP.

51 unocomplexation between the sensor-probe and ALP, which generates blue-green precipitate as an analyt

52 PSA and ALP were measured before each treatment cycle and 4 wk a

53 stanniocalcin 1 (STC1) but not of RUNX2 and ALP in DFCs.

54 mM reduced the expression of OCN, RunX2, and ALP in a time-dependent manner (P <0.001).

55 rode (SPCE) and antibodies against ALP (anti-ALP) were immobilized using carbodiimide bioconjugation

56 ovalent immobilization of ALP antibody (anti-ALP) onto the functionalized paper surface.

57 Considering any ALP decline as a response, no patient with increasing AL

58 decrease from baseline and ALP remission as ALP normalization (if baseline ALP 1.67x-2.8x ULN) or <1

59 The DNA and calcium content, as well as ALP activity of the construct were analyzed.

60 ygotic twin males) were established to assay ALP activity, in vitro mineralization, and gene expressi

61 highly expressed plasma membrane-associated ALP, DNA-lipid-P is converted to lipid-conjugated oligon

62 0.57, 0.83) for abnormal levels of ALT, AST, ALP, and GGT, respectively.

63 liver enzymes and continuous levels of AST, ALP, and GGT.

64 elopment by upregulating the levels of ATF4, ALP and RUNX2, and it stimulated angiogenesis of endothe

65 detection was performed after adding avidin-ALP to perform avidin-biotin reaction; the signal was ge

66 t decreased serum CTX levels and increased b-ALP levels.

67 Levels of serum bone alkaline phosphatase (B-ALP) and myeloperoxidase (MPO) activity in gingival tiss

68 nd IL-10, serum bone alkaline phosphatase (B-ALP) and tartrate-resistant acid phosphatase 5b (TRAP-5b

69 um, phosphorus, bone alkaline phosphatase (b-ALP), and terminal C telopeptide of collagen Type I (CTX

70 affect gingival IL-1beta and IL-10, serum B-ALP and TRAP-5b levels, or alveolar bone compared with c

71 ound in gingival IL-1beta and IL-10, serum B-ALP and TRAP-5b, and calcium and alveolar bone levels be

72 day 18, the animals were sacrificed, serum B-ALP, TRAP-5b, and calcium levels were measured, gingiva

73 oups treated with antioxidant according to B-ALP, MPO, RANKL, and BDI values (P <0.05).

74 ical characterization of the nanoceria-based ALP activity assay was established using a 1-naphthyl ph

75 mol/L); 13 of 20 (65%) patients had baseline ALP >3x ULN.

76 P 1.67x-2.8x ULN) or <1.67x ULN (if baseline ALP >2.8x ULN).

77 remission as ALP normalization (if baseline ALP 1.67x-2.8x ULN) or <1.67x ULN (if baseline ALP >2.8x

78 Because ALP is widely used in enzyme-linked immunosorbent assays

79 quacy of the procedure should be done before ALP is further assumed as a proxy of Vtg in other bivalv

80 EILPs as an intermediate progenitor between ALPs and ILCps.

81 OSX, RUNX2, BMP2, ALP, OCN, BSP and CX43 genes were expressed in hDFC cult

82 % confidence interval (CI) 1.62 to 5.52) but ALP OR 0.92 (95% CI 0.71 to 1.19) and GGT OR 0.88 (95% C

83 o form nanofibrils upon dephosphorylation by ALP, but CES-catalyzed cleavage of the ester bond on the

84 The ensuing T cell responses elicited by ALP or OXP were not limited to particular TCR Vbeta repe

85 cells from patients with MM, as measured by ALP activity at d 14 and Alizarin Red staining at d 21 (

86 herapy, did not otherwise appreciably change ALP and overt proof-of-concept was not established as pe

87 attachment or function, although circulating ALP activity was correlated significantly with incisor c

88 t differentiation markers, including COL1A1, ALP, and OC, in osteoblasts and PDL cells cultured on EM

89 an, type I collagen, Runx2, type X collagen, ALP, Osterix, and MMP13 were measured by RT-qPCR.

90 while the two cell lines exhibit comparable ALP activities.

91 Alkaline Phosphatase-streptavidin conjugate (ALP-Strp).

92 substrates and enzyme labels of conventional ALP assays.

93 of the method for improving the conventional ALP test, as well as for analyzing other enzymatic bioma

94 UDCA administration significantly decreased ALP and sMet levels, and reduced relative liver weight.

95 biosensor is successfully applied to detect ALP in commercial and raw milk samples.

96 Elevated ALP at 1 year, affecting 30% of patients, predicted both

97 ne monitoring, and the cause for an elevated ALP should be sought.

98 t with developmental delay, ID, and elevated ALP, we identified compound-heterozygous variants c.439d

99 Since elevated ALP level is a critical index of some diseases and even

100 ve anchoring on cell membranes with elevated ALP level.

101 steogenic transcription factors and enhanced ALP activity.

102 The sensor has been used to estimate ALP in clinical serum samples, where the level was found

103 (IgM and lysozyme) parameters in LMB, except ALP and CAT.

104 The detection limits were 15fM for ALP and 0.75mM for pNPP.

105 on limit at a signal-to-noise ratio of 3 for ALP was estimated to be 0.02 units/L (~6 pM; 1 ng/mL).

106 tform and has demonstrated functionality for ALP detection in human serum.

107 n to design a turn-on fluorescence probe for ALP sensing.

108 sion level of early osteogenic marker genes, ALP, Runx2, and type I collagen, which play a critical r

109 ccurrence of biliary sludge and lowered GGT, ALP, and ALT.

110 Maximum levels of GGT, ALP, and ALT were lower in the late PN group (P < 0.01).

111 Thirty-seven patients had a high ALP level (19 from group 1 and 18 from group 2).

112 ess hypocalcemia, especially those with high ALP.

113 P and BMP2 demonstrated significantly higher ALP and mineralization activity (P <0.05).

114 Of these, histology, ALP, and TE came out as the most promising.

115 eatment with IL-1beta, TNFalpha and hypoxia, ALP and ZO-1 were decreased, MUC2 increased, and MUC5AC

116 though associated with a modest decrease in ALP after 28 weeks of therapy, did not otherwise appreci

117 ssue formation with significant increases in ALP and DMP1 staining in vivo, whereas DPSC/E106Q cells

118 ts given OCA had at least a 20% reduction in ALP compared with 8% (3 of 37) of patients given placebo

119 nts with a 25% or more relative reduction in ALP had greater reductions in serum alanine aminotransfe

120 Relative reductions in ALP were similar between ursodeoxycholic acid-treated an

121 sphate) that could previously not be used in ALP assays can be conveniently colorimetrically detected

122 ne as a response, no patient with increasing ALP showed a PSA response (P = 0.036).

123 milarly, SSRIs (except citalopram) inhibited ALP and bone mineralization by OB but only at 30 mumol/L

124 ad applications in sensing schemes involving ALP.

125 oid progenitors and, unexpectedly, Irf8(-/-) ALPs produced more neutrophils in vivo than their wild-t

126 enching of BODIPY-ATP can be paired with its ALP-mediated dephosphorylation to design a turn-on fluor

127 A detection limit of 0.04 U/L ALP with a linear range up to 2U/L was obtained with asc

128 that express approximately 15-20 times lower ALP activity compared to SaOs2) not being affected at co

129 ression of up-regulated bone-related markers ALP and COL I.

130 ally significant relative reductions in mean ALP from baseline to the end of the study (P < .0001 all

131 BPS804 treatment increased mean ALP and bone-specific ALP enzymatic activity between day

132 However, at BMP2 concentrations >10 ng/mL, ALP, in vitro mineralization, and osteonectin were downr

133 Trabecular meshwork tissue showed moderate ALP activity at 13 days postinjection.

134 Only 1 in 6 patients with AMAs and normal ALP will develop PBC after 5 years.

135 Among the patients with normal ALP and no evidence of cirrhosis, the 5-year incidence r

136 Keap1 enhanced the gene expression of Nrf2, ALP and wnt5a in cultured primary osteoblasts compared t

137 In the absence of ALP, DNA-lipid-P with its poor hydrophobicity shows only

138 gnal by exploiting the catalytic activity of ALP towards 5-bromo-4-chloro 3-indolyl phosphate (BCIP).

139 cles as redox active catalytic amplifiers of ALP signals.

140 elastography (TE); histology; combination of ALP+histology; and bilirubin.

141 ests only measure the total concentration of ALP but are unable to distinguish enzyme isotypes.

142 ancement was related to the concentration of ALP.

143 Area under the curve of ALP in predicting graft loss from rejection was 0.81 (95

144 d paper biosensor for naked eye detection of ALP in milk samples.

145 hold a potential application in diagnosis of ALP-related diseases or evaluation of ALP functions in b

146 the single molecule activity distribution of ALP in serum reflects the health status of patients.

147 L required by legislation, (2) estimation of ALP in saliva and (3) chlorpyrifos control in commercial

148 sis of ALP-related diseases or evaluation of ALP functions in biological systems.

149 In contrast, GH effect on expression of ALP, IGFBP5 and axin2 in bone were compromised by UL.

150 developed by the covalent immobilization of ALP antibody (anti-ALP) onto the functionalized paper su

151 and resistant (58%) to butyrate induction of ALP activity.

152 The primary outcome was change in level of ALP from baseline (day 0) until the end of the study (da

153 In the extension study, levels of ALP continued to decrease to a mean level of 202 +/- 11

154 Levels of ALP decreased 21%-25% on average from baseline in the OC

155 is an important biomarker, as high levels of ALP in blood can indicate liver disease or bone disorder

156 r evaluation and the physiological levels of ALP in healthy people, the applicability of this assay i

157 FM influenced the levels of ALP, AMY, GLOB, IgM, and MDA (P < 0.05).

158 10 to 50 mg, significantly reduced levels of ALP, gamma-glutamyl transpeptidase, and alanine aminotra

159 eased relative liver weight, serum levels of ALP, sMet, and loss of intracellular glycogen.

160 The immune mechanism of ALP-induced severe cutaneous adverse reactions is poorly

161 susceptible to pharmacological modulation of ALP function.

162 t that aggregation-dependent perturbation of ALP function is a relevant pathogenic mechanism for AD-A

163 upon exposure to the hydrolytic products of ALP.

164 racterize the different activity profiles of ALP isotypes.

165 This probe was used for the screening of ALP inhibitors, including Na3VO4, imidazole, and arginin

166 The stability of ALP in serum allows for the differentiation between old

167 Using uncompetitive inhibitors of ALPs and fluorescent D-tetrapeptides, we delineate that

168 he cancer cell lines express higher level of ALPs are more susceptible to inhibition by the phosphory

169 pulation sampled in the American Life Panel (ALP).

170 was done by comparing the hepatic parameters ALP, GGT, ALT, AST and total bilirubin, also considering

171 The autophagy-lysosomal pathway (ALP) is involved in the degradation of long-lived protei

172 s to explain the autophagy-lysosome pathway (ALP) dysfunction in cells from AD-ANCL patients.

173 ctivation of the autophagy-lysosome pathway (ALP) in a mammalian target of rapamycin (mTOR)-independe

174 t genes from the autophagy-lysosome pathway (ALP), suggesting a key role for this pathway in regulati

175 Median percent ALP reduction from baseline to week 28 was 12.1%.

176 ereas the expression of alkalin phosphatase (ALP) and collagen A I (COL I) genes was analyzed by quan

177 All patients had serum alkaline phosphatase (ALP) > 1.67 x upper limit of normal and total bilirubin

178 , P = 0.007-0.03), and alkaline phosphatase (ALP) (HR 1.05, P < 0.001).

179 % women) and levels of alkaline phosphatase (ALP) 1.5- to 10-fold the upper limit of normal.

180 ls exhibited increased alkaline phosphatase (ALP) activity and expression of osteogenic genes in vitr

181 observations of lower alkaline phosphatase (ALP) activity and higher expression of CD105, a stem cel

182 analogs for detecting alkaline phosphatase (ALP) activity and inhibition.

183 shwork (HTM) cells and alkaline phosphatase (ALP) activity in the angle tissue.

184 RP gradually increased alkaline phosphatase (ALP) activity in the cells in a dose-dependent manner.

185 y for the detection of alkaline phosphatase (ALP) activity is reported based on the surface reactivit

186 erentiation of DFCs by alkaline phosphatase (ALP) activity measurement, alizarin red staining, and el

187 s analyzed in terms of alkaline phosphatase (ALP) activity of KS483-4C3 mouse progenitor cells, and t

188 elated genes, elevated alkaline phosphatase (ALP) activity, and enhanced mineralization.

189 evidenced by increased alkaline phosphatase (ALP) activity, compared to the direct infusion of Dex in

190 nd biosensors based on alkaline phosphatase (ALP) activity/inhibition in the presence of phosphatase

191 ion as demonstrated by alkaline phosphatase (ALP) activity/staining as well as alizarin red S stainin

192 Alkaline phosphatase (ALP) acts as a context-dependent signal for trafficking

193 s had higher levels of alkaline phosphatase (ALP) and alpha-fetoprotein (AFP) and lower level of alan

194 days were assessed for alkaline phosphatase (ALP) and bone mineralization.

195 human osteosarcoma) by alkaline phosphatase (ALP) and fluorescence microscopy were performed to compr

196 minotransferase (ALT), alkaline phosphatase (ALP) and gamma glutamyltransferase (GGT), on diabetes an

197 minotransferase (AST), alkaline phosphatase (ALP) and gamma-glutamytransferase (gamma-GT).

198 arious enzymes such as alkaline phosphatase (ALP) and horseradish peroxidise (HRP).

199 e baseline covariates: alkaline phosphatase (ALP) and prostate-specific antigen (PSA).

200 amyltransferase (GGT), alkaline phosphatase (ALP) and total bilirubin are also reported, although les

201 otein kinase (PKA) and alkaline phosphatase (ALP) are clinically relevant enzymes for a number of dis

202 gonist Sclerostin, and alkaline phosphatase (ALP) are two additional targets of mir-204/211.

203 rease the diffusion of alkaline phosphatase (ALP) at the single-molecule level, in sharp contrast to

204 transaminase (ALT) and alkaline phosphatase (ALP) at ~17.5 years with body mass index (BMI) (n = 3,45

205 nylphosphate (pNPP) by alkaline phosphatase (ALP) bound on paramagnetic-beads was performed into a sm

206 Alkaline phosphatase (ALP) catalyzes the hydrolisis of sodium thiophosphate (T

207 ectroscopy (EIS) based alkaline phosphatase (ALP) detection using gold nanoparticles (AuNPs), electro

208 the tissue-nonspecific alkaline phosphatase (ALP) enzyme.

209 tection sensitivity of alkaline phosphatase (ALP) in electrochemical assays by using nanoceria partic

210 ly can be triggered by alkaline phosphatase (ALP) in solution or in situ by the ALP produced by osteo

211 Alkaline phosphatase (ALP) is a metalloprotein found naturally in raw milk sam

212 Alkaline phosphatase (ALP) is an important biomarker, as high levels of ALP in

213 oglobin levels, higher alkaline phosphatase (ALP) levels and had received more additional therapies c

214 of PDGF-BB levels and alkaline phosphatase (ALP) levels.

215 ent strategy to detect alkaline phosphatase (ALP) under physiological conditions has been developed.

216 alcium, phosphorus and alkaline phosphatase (ALP) values were measured at a series of time points aft

217 Alkaline phosphatase (ALP) was visualized in the vossicles to assess osteoblas

218 factor 2 (Runx2), and alkaline phosphatase (ALP) were assessed in the nicotine-treated (0, 10(-3) ,

219 showed elevated serum alkaline phosphatase (ALP), a GPI-anchored enzyme, in all three affected child

220 ntified, the levels of alkaline phosphatase (ALP), a marker commonly used in clinical diagnostics cor

221 des tissue nonspecific alkaline phosphatase (ALP), an enzyme that promotes mineralization by reducing

222 minotransferase (AST), alkaline phosphatase (ALP), and gamma-glutamyl transaminase (GGT) were measure

223 is of ATP catalyzed by alkaline phosphatase (ALP), and the nanofibers can be re-formed with subsequen

224 asis and liver injury, alkaline phosphatase (ALP), and total and direct bilirubin were evaluated, and

225 ific antigen (PSA) and alkaline phosphatase (ALP), as well as the correlation of PSA changes with the

226 minotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), or total bili

227 Expression of alkaline phosphatase (ALP), in vitro mineralization along with osteonectin exp

228 ranscription factor 2, alkaline phosphatase (ALP), osteocalcin (OC), and collagen1alpha1 (COL1A1), an

229 y was quantified using alkaline phosphatase (ALP), relative liver weight, and confirmed by histologic

230 eogenic specific genes alkaline phosphatase (ALP), Run-related transcription factor 2(RUNX2), and ost

231 We discovered that alkaline phosphatase (ALP), the enzyme broadly used in enzyme-linked immuno-so

232 pid-P) is reported for alkaline phosphatase (ALP)-dependent cell membrane adhesion.

233 detection relies on an alkaline phosphatase (ALP)-labeled competitive immunoassay.

234 videnced by increasing alkaline phosphatase (ALP)-specific activity and osterix, runt-related transcr

235 phosphate (1-NP), for alkaline phosphatase (ALP).

236 g disease progression: alkaline phosphatase (ALP); transient elastography (TE); histology; combinatio

237 ic acid therapy (i.e., alkaline phosphatase [ALP] >1.67x upper limit of normal [ULN] after >/=6 month

238 minotransferase [ALT], alkaline phosphatase [ALP], total bilirubin [TBIL], and albumin) at three time

239 transpeptidase [GGT], alkaline phosphatase [ALP], twice weekly; n = 3,216) were quantified.

240 an enzymatic reaction (alkaline phosphatase, ALP) and a ligand-protein (carbonic anhydrase IX, CA IX)

241 ers 46%; normal serum alkaline phosphatases (ALP) 74%; ALP above 1.5 times the upper limit of normal

242 lesterases (CESs) and alkaline phosphatases (ALPs).

243 ells that overexpress alkaline phosphatases (ALPs).

244 indirect technique, alkali labile phosphate (ALP), that assumes that vitellogenin is the most abundan

245 indicated by increased alkaline phosphates (ALP) activity and calcium deposition.

246 A116T) mice featured 50% reduction in plasma ALP activity compared with wild-type controls.

247 ips between EILPs, all-lymphoid progenitors (ALPs), and ILC precursors (ILCps).

248 differentiate into all lymphoid progenitors (ALPs).

249 er cells by assembly of actin-like proteins (ALPs).

250 y (mouse-anti BoNT/E) followed by RalphaMIgG-ALP/AuNPs.

251 onalized with gold nanoparticles (RalphaMIgG-ALP/AuNPs).

252 i-mouse IgG-alkaline phosphatase (RalphaMIgG-ALP) functionalized with gold nanoparticles (RalphaMIgG-

253 e HLA-B*58:01 molecule for drug recognition, ALP-specific T cells also were restricted to other MHC c

254 The sensor probe has successfully recovered ALP between 108.84% and 172.50% (n = 3) in human serum s

255 PP-PDL cells exhibited significantly reduced ALP and mineralizing capacity, which were rescued by add

256 eolar development and function under reduced ALP, bringing attention to direct effects of HPP on alve

257 In real time (i.e. in about 1 s), ALP (Ascending Ladder Program) calculates the E-values f

258 with alkaline phosphatase (anti-IC-HT2 scFv-ALP) which is able to produce an electroactive reporter

259 to coordinately modulate Runx2, Sclerostin, ALP and Dlx5 proteins at levels appropriate for optimal

260 00 mg led to significant reductions in serum ALP (median reduction -21%; P = 0.029 versus placebo), g

261 Baseline median serum ALP and bilirubin were 348 U/L (interquartile range 288-

262 howed that hypocalcemia was related to serum ALP.

263 eatment increased mean ALP and bone-specific ALP enzymatic activity between days 2 and 29.

264 The ALP-catalyzed hydrolysis of BODIPY-ATP resulted in the f

265 The ALP-catalyzed PPi hydrolysis would disable the complexat

266 gregated CSPalpha are degraded mainly by the ALP but this disease-causing mutation exhibits a faster

267 sphatase (ALP) in solution or in situ by the ALP produced by osteosarcoma cell line, SaOs2.

268 Moreover, FN enhanced the ALP level, calcium deposition and the expression of bone

269 arch have therefore focused on enhancing the ALP in neurodegenerative diseases.

270 -on mode provides a high selectivity for the ALP assay.

271 e DIC analysis, a wide dynamic range for the ALP detection is obtained from 10 to 1000 U/mL with the

272 15 mm (H)] was developed and applied for the ALP detection to demonstrate the instrument-free direct

273 Deficits in the ALP result in protein aggregation, the generation of tox

274 Our data link the ALP to neuronal progranulin: progranulin levels are regu

275 ents demonstrate signal amplification of the ALP activity assay by nanoceria for all three products,

276 We review the regulation of the ALP and TFEB and their impact on neurodegenerative disea

277 anges after interaction with products of the ALP catalyzed reaction, resulting in charge transfer com

278 ity enabled oxidation of the products of the ALP-catalyzed reaction.

279 y, the inhibition effect of phosphate on the ALP activity was also studied.

280 hagy and, in turn, progranulin regulates the ALP.

281 These results show evidence that the ALP method is not providing reliable information about V

282 red the results with those obtained with the ALP method.

283 terize the interaction of nanoceria with the ALP-generated products.

284 TCR, we generated T cell lines that react to ALP or its metabolite oxypurinol (OXP) from HLA-B*58:01(

285 a polyps are significantly more sensitive to ALP compared to control polyps.

286 ed biosensor showed high selectivity towards ALP with negligible interference (k(sel) << 1; n = 3) du

287 The best understood ALP, ParM, has a core set of biochemical properties that

288 In agreement with this, ALN upregulated ALP activity considerably in vossicles.

289 PDL cells and osteoblasts upregulated ALP and in vitro mineralization in a dose-dependent mann

290 atically generated products of commonly used ALP substrates were detected at a screen printing electr

291 novel and rapid approach to profile various ALP isozymes in blood via a single-molecule-analysis pla

292 with a subsample of highly educated, wealthy ALP subjects as well as elite law school students and un

293 mbly of a chiral double helix is formed when ALP is present to consume ATP.

294 cific interaction of analyte (antibody) with ALP-labeled antibody can be detected through formation o

295 IX overexpressed cells, when cocultured with ALP overexpressed cells, where the nanoassembly presumab

296 ate (FDP) and immuno-complex conjugated with ALP.

297 nge, 2.4-6.5) was moderately correlated with ALP (r = 0.60, P < 0.0001) and with PSA (r = 0.38, P = 0

298 Patients with ALP >= 566 U/L had lower calcium compared to patients wi

299 had lower calcium compared to patients with ALP < 566 U/L up to a month after RFA (P < 0.05).

300 s significantly longer than in patients with ALP decline only (median, 77 wk; P = 0.029).